Key result
Nanophospholipid doxorubicin decreases blood cell association and increases plasma levels vs free doxorubicin in vitro.
Why the study?
Does a nanophospholipid formulation of doxorubicin alter its distribution in blood and plasma compared to free doxorubicin in vitro?
Does a nanophospholipid formulation of doxorubicin alter its distribution in blood and plasma compared to free doxorubicin in vitro?
Formulating doxorubicin in nanophospholipids alters its blood distribution in vitro, decreasing cell association and increasing HDL binding, which may impact its biodistribution and antitumor activity.
May alter doxorubicin blood distribution in vivo; hypothesis-generating and requires animal validation before clinical consideration.
The drug composition based on the plant phospholipids and the antitumor drug doxorubicin (particle size <30 nm) was obtained using original technology elaborated in the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences). In in vitro experiments demonstrated decreased drug association with blood cells for this nanophospholipid form as compared with free doxorubicin. This was accompanied by a with corresponding increase in its plasma level ans also by drug redistribution from plasma protein fraction to high density lipoproteins. Significance of these changes for doxorubicin biodistributon and antitumor activity is discussed.
No takes yet. Share an insight, caveat, or question.
Zykova et al. (2012) studied this question. Nanophospholipid formulation of doxorubicin vs. Free doxorubicin was evaluated on Drug association with blood cells and plasma distribution. In vitro experiments demonstrated that a nanophospholipid formulation of doxorubicin decreased drug association with blood cells and increased plasma levels compared with free doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: